Compare EM & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EM | PALI |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 296.7M | 333.6M |
| IPO Year | 2021 | 2019 |
| Metric | EM | PALI |
|---|---|---|
| Price | $1.20 | $1.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $1.25 | ★ $11.29 |
| AVG Volume (30 Days) | 130.8K | ★ 4.3M |
| Earning Date | 06-02-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 97.06 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $260,000.00 |
| Revenue This Year | $3.30 | N/A |
| Revenue Next Year | $5.26 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1500.39 |
| 52 Week Low | $1.01 | $0.55 |
| 52 Week High | $1.46 | $2.86 |
| Indicator | EM | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 66.07 | 47.71 |
| Support Level | $1.16 | $1.57 |
| Resistance Level | $1.42 | $2.05 |
| Average True Range (ATR) | 0.02 | 0.19 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 73.68 | 17.67 |
Smart Share Global Ltd is a consumer tech company providing mobile device charging services through an extensive online and offline network in China. It provides service through power banks, placed in POIs operated by location partners, such as entertainment venues, restaurants, shopping centers, hotels, transportation hubs, and public spaces. Geographically, the company generates revenue from the PRC. The company has two segments, the mobile device charging segment and the PV business segment. The company generates the majority of its revenue from the mobile device charging segment.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.